Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS
Date:7/31/2014

ste Program, as research funding under the Company's collaboration with Firmenich expired in June 2013.

Commercial revenues were $1.4 million for the second quarter of 2014 and $1.5 million for the second quarter of 2013.  Commercial revenues were $2.9 million for each of the six months ended June 30, 2014 and 2013. These results reflect non-recurring revenues in the second quarter of 2013 related to a Savory Taste Program collaboration, as well as direct sales and increases in other commercial revenues from the Savory and the Sweet Taste Programs in the first half of 2014.

Research, development and patents expenses, including stock-based compensation expenses, decreased to $6.6 million for the second quarter of 2014 from $7.0 million in the second quarter of 2013.  For the six month periods ended June 30, research, development and patents expenses decreased to $13.6 million in 2014 from $14.3 million in 2013.  The primary factor for the decreases from 2013 to 2014 was reduced outside services costs for safety studies to support regulatory filings.

Selling, general and administrative expenses, including stock-based compensation expenses, were $3.3 million for the second quarter of 2014 and $2.9 million for the second quarter of 2013.  Selling, general and administrative expenses for the six months ended June 30, 2014 were $6.4 million compared to $6.0 million for the six months ended June 30, 2013.  The increases from 2013 to 2014 were primarily due to increased non-cash stock-based compensation expenses in 2014 resulting from a higher fair value for stock options granted in 2014 based on the higher price of Senomyx's common stock.

The net loss for each of the quarters ended June 30, 2014 and 2013 was $0.06 per share.  The net loss for the six months ended June 30, 2014 was $0.11 per share compared to $0.13 per share for the six months ended June 30, 2013.

Financial Outlook:"Fina
'/>"/>

SOURCE Senomyx, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 16TH ANNUAL NEEDHAM GROWTH CONFERENCE
2. SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER FINANCIAL RESULTS
3. Senomyx Announces Management Update
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
5. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
7. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
9. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
10. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
11. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
... Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 ... presentation, Tuesday, May 19, 3:35 p.m. PDT - - ... - BRISBANE, Calif., May 14 InterMune, Inc. (Nasdaq: ... presentation and two poster discussion presentations related to the company,s ...
... with substantially increased capacity, for continued ... announced today robust double digit growth in sales, improved ... quarter ended March 31, 2009. , In a news ... "Our 43% growth in the first half of 2009 ...
Cached Biology Technology:Ausio Pharmaceuticals to Present at Bio(R) 2009 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... MOUNTAIN VIEW, CA January 25, 2011 23andMe,s ... both phenotypic and genetic data from 500 individuals diagnosed ... way towards its goal of building a sarcoma research ... completed its Independent Sarcoma Scientific Advisory Committee with the ...
... lethal form of brain cancer and the disease that ... efforts, even when attacked simultaneously on several fronts. One ... flexibility, discovered researchers at the Salk Institute for Biological ... glioblastoma cells can shift gears and morph into blood ...
... Baltimore, Md. (January 24, 2011) A research effort designed ... a research hatchery could end up helping Chesapeake Bay watermen ... shell crabs perishing before reaching the market. The findings, published ... that the transmission of a crab-specific virus in diseased and ...
Cached Biology News:23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 3Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: